Related Experiment Videos
Anti-CD30 antibody-based therapy
1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Abstract:
The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms.
Insights
Antibody-based therapies targeting CD30 show promise for treating CD30+ neoplasms. These therapies leverage CD30's specific expression on cancer cells for targeted treatment, offering new therapeutic options.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- CD30 is highly expressed on certain cancer cells but minimally on normal tissues.
- This differential expression makes CD30 an attractive target for cancer therapies.
- Anti-CD30 antibodies have demonstrated potential in modulating immune responses and delivering therapeutic payloads.
Purpose of the Study:
- To review the therapeutic potential of anti-CD30 antibodies and related conjugates.
- To evaluate anti-CD30-based strategies for treating CD30-positive neoplasms.
- To summarize recent preclinical and clinical findings on anti-CD30 therapies.
Main Methods:
- Review of preclinical and clinical studies involving anti-CD30 antibodies.
- Analysis of various anti-CD30 therapeutic formats including bispecific antibodies, immunotoxins, and radioimmunoconjugates.
- Evaluation of CD30 expression patterns in neoplasms versus normal tissues.
Main Results:
- Anti-CD30 antibodies function as signaling molecules and immune system modulators.
- Preclinical and clinical investigations show efficacy of various anti-CD30 constructs.
- Therapeutic strategies include unmodified antibodies, bispecific antibodies, immunotoxins, and radioimmunoconjugates.
Conclusions:
- Anti-CD30-based therapies represent a promising new class of treatments for CD30+ cancers.
- Targeting CD30 offers a viable strategy for developing novel cancer therapeutics.
- Further clinical development is warranted for these promising anti-CD30-based modalities.